The Women's Cancer research program is built on Fox Chase's noted strengths in the study and treatment of breast and gynecologic cancers, and is home to the Fox Chase-Penn Ovarian SPORE Grant. The program priority is to focus on the development of translational studies of prevention, risk reduction, behavioral medicine and treatment through interactions of basic science and clinical investigators.
With the tools at the disposal of its researchers, the program seeks to use high-throughput molecular analyses in studying cancer tissue specimens in order to discover and validate new therapeutic targets. Furthermore, the program investigates novel enrichment technologies for the detection and characterization of micrometastatic disease in breast cancer.
The goals of the program include:
Developing preclinical models to assess prevention and treatment
Discovering novel biomarkers of risk and progression of disease
Identifying and studying micrometastatic disease
Identifying and targeting cancer stem cells that drive aggressive cancers
Elucidating the contributions of the microenvironment to cancer development and progression
Studying the role of estrogen and xenoestrogens in breast development and cancer
Defining the windows of susceptibility of the human breast to cancer
Enhancing the collection and annotation of clinical samples to support basic and clinical studies of cancer etiology, diagnosis, and treatment.
Team |
 Co-leaders Dr. Jeff Boyd, Dr. Massimo Cristofanilli
|
Researchers in the program work in close collaboration with - and some are, in fact, clinicians in Fox Chase's Women's Cancer Center, one of the leading facilities of its kind among NCI-designated comprehensive cancer centers. Such close ties will enhance the research program's ability to move promising pre-clinical strategies from out of the laboratory and into investigational clinical trials. Read More.
|
Print this Page
For Information about cancer or